{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:35:12Z","timestamp":1786383312515,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In a family with IH, a rare high turnover bone disease, two older siblings were wheelchair-bound with severe skeletal deformity by age 15. Their youngest affected sibling was treated intensively with intravenous bisphosphonates for 3 years. The treatment was well tolerated and prevented the development of deformity and disability.<\/jats:p>\n               <jats:p>Introduction: Idiopathic hyperphosphatasia (IH, also known as juvenile Paget's disease) is a rare genetic bone disease characterized by very high bone turnover and progressive bony deformity. Inhibitors of bone resorption have been used to suppress bone turnover in the short term, but there is no published data on long-term efficacy.<\/jats:p>\n               <jats:p>Materials and Methods: An 11-year-old girl with IH, who had two severely affected older siblings, presented with progressive deformity and deafness and long bone fractures. Conventional pediatric doses of pamidronate had failed to prevent clinical deterioration or suppress bone turnover completely. Intensive bisphosphonate therapy (frequent 5-mg ibandronate infusions) was given to try and arrest progression of the skeletal disease. Growth and development, pure tone audiometry, biochemistry, radiology, densitometry (DXA), and bone histology were monitored.<\/jats:p>\n               <jats:p>Results: A total of 45 mg ibandronate was given over 3 years until skeletal maturity was reached (20, 15, and 10 mg for years 1\u20133, respectively). Ibandronate treatment was well tolerated, and biochemical markers of bone turnover suppressed to within the age-appropriate normal range There was some progression of her thoracic kyphosis, but she had no further fractures and remained mobile and active at an age when her siblings had become wheelchair-bound. A significant recovery of hearing (p &amp;lt; 0.01) was documented, particularly at low frequencies. Radiographs showed improvement in spinal osteoporosis and cortical bone dimensions and arrest of progressive acetabular protrusion. Areal bone density increased substantially (lumbar spine z-score from \u22122.2 to + 1.8). Tetracycline-labeled bone biopsy specimens were taken before and after 18 months of intensive treatment. The second biopsy showed suppression of bone turnover and a doubling of trabecular thickness, with no mineralization defect, and no osteopetrosis.<\/jats:p>\n               <jats:p>Conclusions: Intensive bisphosphonate treatment prevented the development of deformity and disability and improved hearing in this child with IH. The dose of bisphosphonate, which is substantially greater than is usually used in pediatric bone disease, had no adverse effects, in particular on bone mineralization.<\/jats:p>","DOI":"10.1359\/jbmr.040127","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T07:02:13Z","timestamp":1146121333000},"page":"703-711","source":"Crossref","is-referenced-by-count":45,"title":["Treatment of Idiopathic Hyperphosphatasia With Intensive Bisphosphonate Therapy"],"prefix":"10.1093","volume":"19","author":[{"given":"Tim","family":"Cundy","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wheadon","sequence":"additional","affiliation":[{"name":"Kelston Deaf Education Centre, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"King","sequence":"additional","affiliation":[{"name":"Department of Pathology, Middlemore Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019204922200_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","article-title":"Osteoprotegerin deficiency and juvenile Paget's disease","volume":"247","author":"Whyte","year":"2002","journal-title":"N Engl J Med"},{"key":"2024013019204922200_bib2","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/hmg\/11.18.2119","article-title":"A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype","volume":"11","author":"Cundy","year":"2002","journal-title":"Hum Mol Genet"},{"key":"2024013019204922200_bib3","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1359\/jbmr.2003.18.12.2095","article-title":"Idiopathic hyperphosphatasia: Relationships between phenotype and mutations in the gene encoding osteoprotegerin","volume":"18","author":"Chong","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019204922200_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1259\/0007-1285-47-553-9","article-title":"Healing of the bones in juvenile Paget's disease treated by human calcitonin","volume":"47","author":"Doyle","year":"1974","journal-title":"Br J Radiol"},{"issue":"Suppl","key":"2024013019204922200_bib5","first-page":"341S","article-title":"Hereditary bone dysplasia with hyperphosphatasemia:response to synthetic human calcitonin","volume":"5","author":"Horwith","year":"1976","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024013019204922200_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2214\/ajr.129.1.29","article-title":"Calcitonin treatment in hereditary bone dysplasia with hyperphosphatasemia: A radiographic and histologic study of bone","volume":"129","author":"Whalen","year":"1977","journal-title":"Am J Roentgenol"},{"key":"2024013019204922200_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1302\/0301-620X.59B4.562883","article-title":"Familial idiopathic hyperphosphatasia","volume":"59","author":"Blanco","year":"1977","journal-title":"J Bone Joint Surg Br"},{"key":"2024013019204922200_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2214\/ajr.132.4.541","article-title":"Familial hyperphosphatasemia: Diagnosis in early infancy and response to human thyrocalcitonin therapy","volume":"132","author":"Dunn","year":"1979","journal-title":"Am J Roentgenol"},{"key":"2024013019204922200_bib9","first-page":"642","article-title":"Chronic idiopathic hyperphosphatasia: Report of a case treated with pamidronate and a review of the literature","volume":"19","author":"Spindler","year":"1992","journal-title":"J Rheumatol"},{"key":"2024013019204922200_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0169-6009(92)90924-3","article-title":"Familial idiopathic hyperphosphatasia: Response to long-term treatment with pamidronate","volume":"19","author":"Cassinelli","year":"1992","journal-title":"Bone Miner"},{"key":"2024013019204922200_bib11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jbmr.5650090519","article-title":"Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate","volume":"9","author":"Singer","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024013019204922200_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jbmr.5650110118","article-title":"Juvenile Paget disease: Life-long features of a mildly affected young woman","volume":"11","author":"Golob","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019204922200_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s002470050708","article-title":"Calcitonin treatment in osteoectasia with hyperphosphatasia (juvenile Paget's disease)","volume":"29","author":"T\u00fcys\u00fcz","year":"1999","journal-title":"Pediatr Radiol"},{"key":"2024013019204922200_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/JPEM.2000.13.2.217","article-title":"Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia","volume":"13","author":"Demir","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2024013019204922200_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2024013019204922200_bib16","volume-title":"Assessment of Skeletal Maturity and Prediction of Adult Height","author":"Tanner","year":"1983","edition":"2nd ed."},{"key":"2024013019204922200_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1148\/100.3.509","article-title":"Bone measurements in the differential diagnosis of osteopenia and osteoporosis","volume":"100","author":"Garn","year":"1971","journal-title":"Radiology"},{"key":"2024013019204922200_bib18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1172\/JCI7060","article-title":"The differing tempo of growth in bone size, mass and density in girls is region specific","volume":"104","author":"Bass","year":"1999","journal-title":"J Clin Invest"},{"key":"2024013019204922200_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S8756-3282(99)00257-4","article-title":"Normative data for iliac bone histomorphometry in growing children","volume":"26","author":"Glorieux","year":"2000","journal-title":"Bone"},{"key":"2024013019204922200_bib20","first-page":"145","article-title":"Congenital hyperphosphatasia (juvenile Paget's disease)","volume":"20","author":"Eroglu","year":"1976","journal-title":"Ann Radiol"},{"key":"2024013019204922200_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0720-048X(99)00128-X","article-title":"Hyperphosphatasemia: Report of three cases","volume":"35","author":"Bonakdarpour","year":"2000","journal-title":"Eur J Radiol"},{"key":"2024013019204922200_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/adc.52.6.473","article-title":"Renal osteodystrophy in non-dialysed adolescents: Long-term treatment with 1\u03b1-hydroxycholecalciferol","volume":"52","author":"Kanis","year":"1977","journal-title":"Arch Dis Child"},{"key":"2024013019204922200_bib23","volume-title":"Bisphosphonates in Bone Disease\u2014From the Laboratory to the Patient","author":"Fleisch","year":"1995"},{"issue":"Suppl","key":"2024013019204922200_bib24","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1016\/S8756-3282(99)00072-1","article-title":"Ibandronate treatment in Paget's disease of bone","volume":"24","author":"Grauer","year":"1999","journal-title":"Bone"},{"key":"2024013019204922200_bib25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"key":"2024013019204922200_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"2024013019204922200_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0378-5955(94)00196-W","article-title":"Hearing loss in Paget's disease of bone: The relationship between pure-tone thresholds and mineral density of the cochlear capsule","volume":"83","author":"Monsell","year":"1995","journal-title":"Hear Res"},{"key":"2024013019204922200_bib28","volume-title":"Pathophysiology and Treatment of Paget's Disease of Bone","author":"Kanis","year":"1991"},{"key":"2024013019204922200_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/BF00173660","article-title":"The detrimental effect of aminohydroxypropylidene bisphosphonate (APD) in otospongiosis","volume":"248","author":"Boumans","year":"1991","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2024013019204922200_bib30","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.040127","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/5\/703\/56475814\/5650190502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/5\/703\/56475814\/5650190502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:06:32Z","timestamp":1710342392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/19\/5\/703-711\/7592907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2004,5,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.040127","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,5,1]]},"published":{"date-parts":[[2004,5,1]]}}}